Q3 2025 confirmed what many venture observers suspected: startups deploying or developing AI technologies continue to command higher valuations than their non-AI peers, with 2.5x higher revenue multiples (20x vs. 8x). That gap is partially due to the increased presence of AI in mega deals (i.e., equity financing events with total capital raised of $100M or more).
The healthcare sector saw the most significant growth in AI capital raised premiums at Series A and AI pre-money valuation premiums at Series A. The industry’s rapid integration of AI technologies has led to use cases in clinical efficiency, patient engagement, and compliance that drive both investor enthusiasm and tangible results.
Despite outperforming non-AI companies, Series A premiums for AI startups declined across most sectors compared to 2024, raising questions about the sustainability of elevated AI valuations. Given ongoing debate about the technology, some market observers have expressed concern over its long-term performance.
Key Takeaway: AI startups continue to enjoy substantial valuation advantages, but the softening of Series A premiums compared to last year signals that investors may begin to look beyond the hype.
[View source.]
